JP2016530265A - 免疫調節のための４−メチルウンベリフェロン処置 - Google Patents

免疫調節のための４−メチルウンベリフェロン処置 Download PDF

Info

Publication number
JP2016530265A
JP2016530265A JP2016534801A JP2016534801A JP2016530265A JP 2016530265 A JP2016530265 A JP 2016530265A JP 2016534801 A JP2016534801 A JP 2016534801A JP 2016534801 A JP2016534801 A JP 2016534801A JP 2016530265 A JP2016530265 A JP 2016530265A
Authority
JP
Japan
Prior art keywords
compound
disease
methylumbelliferone
autoimmune
effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016534801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530265A5 (enExample
Inventor
ポール ボリーキー，
ポール ボリーキー，
ナディーン ナギー，
ナディーン ナギー，
トーマス ワイト，
トーマス ワイト，
ヘドウィグ エフ． カイパース，
ヘドウィグ エフ． カイパース，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2016530265A publication Critical patent/JP2016530265A/ja
Publication of JP2016530265A5 publication Critical patent/JP2016530265A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016534801A 2013-08-12 2014-08-12 免疫調節のための４−メチルウンベリフェロン処置 Withdrawn JP2016530265A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361865084P 2013-08-12 2013-08-12
US61/865,084 2013-08-12
PCT/US2014/050770 WO2015023691A2 (en) 2013-08-12 2014-08-12 4-methylumbelliferone treatment for immune modulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019095974A Division JP2019135262A (ja) 2013-08-12 2019-05-22 免疫調節のための４−メチルウンベリフェロン処置

Publications (2)

Publication Number Publication Date
JP2016530265A true JP2016530265A (ja) 2016-09-29
JP2016530265A5 JP2016530265A5 (enExample) 2017-09-14

Family

ID=52468796

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016534801A Withdrawn JP2016530265A (ja) 2013-08-12 2014-08-12 免疫調節のための４−メチルウンベリフェロン処置
JP2019095974A Pending JP2019135262A (ja) 2013-08-12 2019-05-22 免疫調節のための４−メチルウンベリフェロン処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019095974A Pending JP2019135262A (ja) 2013-08-12 2019-05-22 免疫調節のための４−メチルウンベリフェロン処置

Country Status (5)

Country Link
US (2) US10285976B2 (enExample)
EP (1) EP3033416A4 (enExample)
JP (2) JP2016530265A (enExample)
CN (1) CN105579578A (enExample)
WO (1) WO2015023691A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022514672A (ja) * 2018-12-20 2022-02-14 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ヒアルロナン合成阻害のための４－メチルウンベリフェリルグルクロニド
JP2022554230A (ja) * 2019-10-25 2022-12-28 クウォク ジェシカ 神経系の状態の処置

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9833614B1 (en) 2012-06-22 2017-12-05 Nevro Corp. Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods
CA2988306A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
JP6952350B2 (ja) * 2016-06-10 2021-10-20 国立大学法人東北大学 インスリン分泌促進剤又はインスリン抵抗性改善剤
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
US11278518B2 (en) 2017-01-13 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of treatment using 4-methylumbelliferone and derivatives thereof
US10370400B2 (en) * 2017-01-13 2019-08-06 The Board Of Trustees Of The Leland Stanford Junior University 4-methylumbelliferone derivatives for treatment for immune modulation
WO2019165319A1 (en) * 2018-02-23 2019-08-29 The Board Of Trustees Of The Leland Stanford Junior University The use of 4-methylumbelliferone to prevent immune rejection in cases of tissue transplantation
KR20200132988A (ko) * 2018-03-29 2020-11-25 네브로 코포레이션 제2형 당뇨병을 포함한 혈당 이상을 치료하고 그리고/또는 hba1c 수준을 감소시키기 위한 치료 조절과, 연관 시스템들 및 방법들
BR112022018741A2 (pt) * 2020-04-03 2022-11-01 Standard Of Care Corp Composições de hialuronidase e/ou 4-metilumbeliferona aerossolizadas e métodos de uso das mesmas para tratar doenças ou distúrbios respiratórios
CN114425050A (zh) * 2022-02-09 2022-05-03 深圳大学 一种4-甲基伞形酮在制备抗过敏药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517030A (ja) * 1999-05-24 2004-06-10 アバロン バイオサイエンシーズ， インコーポレイテッド グリコシルトランスフェラーゼインヒビター
JP2005530778A (ja) * 2002-05-17 2005-10-13 フォースト・ファーマシューティカルス 神経障害の予防および／または治療のための方法
WO2012012300A2 (en) * 2010-07-20 2012-01-26 Halozyme, Inc. Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4451933B2 (ja) * 1996-12-27 2010-04-14 住友化学株式会社 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法
GB9722600D0 (en) * 1997-10-24 1997-12-24 Bio Monde Holdings Internation Pharmaceutical compositon
DE60037113T2 (de) 1999-05-24 2008-09-18 Abaron Biosciences, Inc., Del Mar Glycosyltransferase inhibitoren
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
WO2004082610A2 (en) 2003-03-14 2004-09-30 Brigham And Women's Hospital, Inc. Modulation of hyaluronan and cd44 interaction and uses thereof in treating disorders
EP1660072A2 (en) * 2003-07-29 2006-05-31 Universitätsklinikum Münster Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer
JP2013509882A (ja) 2009-11-05 2013-03-21 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ カテナ：漿液性癌幹細胞
DK2833905T3 (en) * 2012-04-04 2018-07-30 Halozyme Inc Combination therapy with hyaluronidase and a tumor-targeted taxane
CN102846598A (zh) * 2012-08-03 2013-01-02 广州康臣药物研究有限公司 香豆素在制备AGEs形成抑制剂中的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517030A (ja) * 1999-05-24 2004-06-10 アバロン バイオサイエンシーズ， インコーポレイテッド グリコシルトランスフェラーゼインヒビター
JP2005530778A (ja) * 2002-05-17 2005-10-13 フォースト・ファーマシューティカルス 神経障害の予防および／または治療のための方法
WO2012012300A2 (en) * 2010-07-20 2012-01-26 Halozyme, Inc. Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARTHRITIS AND RHEUMATISM, 2013.05, VOL.65, NO.5, PP.1160-1170, JPN6018014721, ISSN: 0003960800 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022514672A (ja) * 2018-12-20 2022-02-14 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ヒアルロナン合成阻害のための４－メチルウンベリフェリルグルクロニド
JP2022554230A (ja) * 2019-10-25 2022-12-28 クウォク ジェシカ 神経系の状態の処置

Also Published As

Publication number Publication date
EP3033416A2 (en) 2016-06-22
CN105579578A (zh) 2016-05-11
WO2015023691A2 (en) 2015-02-19
US10285976B2 (en) 2019-05-14
US20160184262A1 (en) 2016-06-30
US20200101042A1 (en) 2020-04-02
WO2015023691A3 (en) 2015-04-09
EP3033416A4 (en) 2017-02-08
JP2019135262A (ja) 2019-08-15

Similar Documents

Publication Publication Date Title
JP2019135262A (ja) 免疫調節のための４−メチルウンベリフェロン処置
US20220040126A1 (en) Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders
US10370400B2 (en) 4-methylumbelliferone derivatives for treatment for immune modulation
JPS6323817A (ja) ブロモクリプチンの新用途
JP5404406B2 (ja) 細胞外マトリクスの分解の阻害
US20240082312A1 (en) Compositions and methods for williams syndrome (ws) therapy
US20150051137A1 (en) Peptide and uses therefor
US20180326021A1 (en) Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders
EP2889039B1 (en) Preparation for preventing or treating type i diabetes
US20090312255A1 (en) Stimulation of trpv1+ sensory neurons to control beta-cell stress and islet inflammation in diabetes
US20220143128A1 (en) Methods for treating traumatic brain injury
US9839671B2 (en) Peptide and uses therefor
AU2014306775A1 (en) 4-methylumbelliferone treatment for immune modulation
AU2019403402A1 (en) 4-methylumbelliferyl glucuronide for hyaluronan synthesis inhibition
Nagy et al. Hyaluronan in Autoimmunity and Immune Dysregulation
US11771672B2 (en) Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies
AU2018315052A1 (en) Type 1 diabetes therapy
JP2020512010A (ja) 自己免疫疾患及び糖尿病を治療するウイルスベクター、その構築方法及び応用
Milton Chronic Systemic Manipulation of Axonal Inhibitory Perineuronal Net and rPTPσ Promotes Forelimb Recovery and Neuroplasticity
WO2019165319A1 (en) The use of 4-methylumbelliferone to prevent immune rejection in cases of tissue transplantation
JP2023151051A (ja) 骨格筋ＴｙｐｅＩ細胞への分化誘導剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190522

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190703

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190705